Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Spokane Joint Replacement Center
- Target Recruit Count
- 51
- Registration Number
- NCT01267279
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Target Recruit Count
- 320
- Registration Number
- NCT01234129
- Locations
- 🇲🇽
Tertiary reference oncology center, Mexico, Distrito Federal, Mexico
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
- Conditions
- HIV InfectionOsteoporosisBone LossOsteopenia
- Interventions
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 63
- Registration Number
- NCT01228318
- Locations
- 🇺🇸
Grady Infectious Diseases Clinic (Ponce Center), Atlanta, Georgia, United States
Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis
- Conditions
- Hip Osteoarthritis
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01218035
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01197300
- Locations
- 🇬🇧
Novartis Investigative Site, West Midlands, Birmingham, United Kingdom
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
- Conditions
- Ductal Carcinoma in SituEstrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 63
- Registration Number
- NCT01194440
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Zoledronic Acid in MS-patients With Osteoporosis
- Conditions
- OsteoporosisMultiple Sclerosis
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 29
- Registration Number
- NCT01166178
- Locations
- 🇩🇪
Novartis Investigative Site, Siegen, Germany
🇩🇪Novartis investigative site, Stade, Germany
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
- Conditions
- Osteoporosis, Osteopenia
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 33
- Registration Number
- NCT01153425
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
- Conditions
- First or Second Line HER2-negative Breast CancerMetastatic Disease Without Bone Metastasis
- Interventions
- Drug: Standard TherapyDrug: Zoledronic acid
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT01129336
- Locations
- 🇺🇸
Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States
🇺🇸Wilshire Oncology Medical Group, La Verne, California, United States
🇺🇸Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- Drug: cyclophosphamideDrug: docetaxelDrug: doxorubicin hydrochlorideProcedure: neoadjuvant therapyDrug: zoledronic acid
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Borstkanker Onderzoek Groep
- Target Recruit Count
- 250
- Registration Number
- NCT01099436
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.